Ionis Pharmaceuticals SEC Filings

JPMorgan Chase Financial Company LLC is offering Auto Callable Accelerated Barrier Notes linked individually to the Nasdaq-100 (NDX), Russell 2000 (RTY) and S&P 500 (SPX) indices. The notes are unsecured, unsubordinated obligations of JPMorgan Chase Financial and are fully and unconditionally guaranteed by JPMorgan Chase & Co. Key commercial terms are still preliminary and will be finalized on or about July 28 2025, with settlement expected on July 31 2025 and maturity on August 2 2028.

• Automatic call feature: If on any non-final Review Date (July 31 2026 or July 28 2027) the closing level of each index is at or above 100 % of its Initial Value, the notes will be redeemed early for $1,000 plus the applicable Call Premium Amount (≥ 12.55 % or ≥ 25.10 %).
• Upside participation at maturity: If not called and all three indices finish above their Initial Values on the final Review Date, investors receive 1.50× the percentage gain of the worst-performing index (uncapped).
• Barrier protection: 70 % of Initial Value for each index. If any index closes below its barrier on the final Review Date, principal is reduced one-for-one with the decline of the worst performer, exposing investors to losses up to 100 %.
• Indicative economics: Estimated value today is $945.30 per $1,000 note (minimum ≥ $900.00), reflecting selling commissions (≤ $30) and structuring/hedging costs included in the $1,000 issue price.
• Liquidity & credit: The notes will not be listed; secondary prices depend on JPMS bid. Payment is subject to the credit of both the issuer and guarantor.

Investors forgo periodic coupons and dividends, face potential early redemption that caps upside, and assume index, market-volatility, credit and liquidity risks as detailed in the extensive “Selected Risk Considerations.”

JPMorgan Chase Financial Company LLC is offering Auto Callable Accelerated Barrier Notes linked individually to the Nasdaq-100 (NDX), Russell 2000 (RTY) and S&P 500 (SPX) indices. The notes are unsecured, unsubordinated obligations of JPMorgan Chase Financial and are fully and unconditionally guaranteed by JPMorgan Chase & Co. Key commercial terms are still preliminary and will be finalized on or about July 28 2025, with settlement expected on July 31 2025 and maturity on August 2 2028.

• Automatic call feature: If on any non-final Review Date (July 31 2026 or July 28 2027) the closing level of each index is at or above 100 % of its Initial Value, the notes will be redeemed early for $1,000 plus the applicable Call Premium Amount (≥ 12.55 % or ≥ 25.10 %).
• Upside participation at maturity: If not called and all three indices finish above their Initial Values on the final Review Date, investors receive 1.50× the percentage gain of the worst-performing index (uncapped).
• Barrier protection: 70 % of Initial Value for each index. If any index closes below its barrier on the final Review Date, principal is reduced one-for-one with the decline of the worst performer, exposing investors to losses up to 100 %.
• Indicative economics: Estimated value today is $945.30 per $1,000 note (minimum ≥ $900.00), reflecting selling commissions (≤ $30) and structuring/hedging costs included in the $1,000 issue price.
• Liquidity & credit: The notes will not be listed; secondary prices depend on JPMS bid. Payment is subject to the credit of both the issuer and guarantor.

Investors forgo periodic coupons and dividends, face potential early redemption that caps upside, and assume index, market-volatility, credit and liquidity risks as detailed in the extensive “Selected Risk Considerations.”

Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:

• 11,518 non-qualified stock options with a strike price of $39.94.
• 5,220 restricted stock units (RSUs).

Under the company’s Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.

Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.

After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.

Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:

• 11,518 non-qualified stock options with a strike price of $39.94.
• 5,220 restricted stock units (RSUs).

Under the company’s Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.

Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.

After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.

Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:

• 11,518 non-qualified stock options with a strike price of $39.94.
• 5,220 restricted stock units (RSUs).

Under the company’s Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.

Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.

After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.

Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:

• 11,518 non-qualified stock options with a strike price of $39.94.
• 5,220 restricted stock units (RSUs).

Under the company’s Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.

Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.

After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.

Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:

• 11,518 non-qualified stock options with a strike price of $39.94.
• 5,220 restricted stock units (RSUs).

Under the company’s Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.

Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.

After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.

Form 4 filing for Apollo Global Management, Inc. (APO): Director Mitra O’Neill (professionally known as Mitra Hormozi) reported the grant of 1,446 restricted stock units (RSUs) on 07/01/2025 under the company’s 2019 Omnibus Equity Incentive Plan. Each RSU converts into one share of APO common stock upon vesting, with settlement deferred until the director leaves the board. Following the award, the director’s direct holdings total 30,344 shares (including 7,049 RSUs already held). In addition, 2,500 shares are indirectly held through an entity controlled by the director’s spouse. No shares were sold, no cash changed hands, and no derivative securities were involved. This filing reflects routine, service-based equity compensation aimed at aligning director interests with shareholders rather than signaling a change in company fundamentals.